Search Results - cxxxxx

81 Results Sort By:
Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs
Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem...
Published: 10/28/2024   |   Inventor(s): Deborah Sammons, Shirley Robertson, Jerome Smith
Keywords(s): AE1BXX, AE2XXX, AE3XXX, Anti-neoplastic, CANCER, CANCER CHEMOTHERAPY, CANCEROUS, CB5XXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDXXXX, Contaminant, Contaminants, Contaminated, contamination, CXXXXX, Detection, detection system, Direct, DRUGS, Kits, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DART, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reading, SAFE, SAFETY, Surface, TOXIC, Toxicity, TOXIGENIC, TOXINS, VCXXXX, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, XHXXXX, XIXXXX, YBXXXX, YEXXXX
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Cardiology, Application > Research Materials, Application > Occupational Safety and Health, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Consumer Products, TherapeuticArea > Dental, TherapeuticArea > Oncology, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology
Therapeutic, Bifunctional Janus Microparticles with Spatially Segregated Surface Proteins and Methods of Production
CDC researchers have developed a fabrication process to create bifunctional microparticles displaying two distinct proteins that are spatially segregated onto a single hemispheric surface. At present, there is no described way of producing biological microparticles with two distinct types of separated proteins. Bifunctional Janus particles generated...
Published: 4/8/2024   |   Inventor(s): David White, Jennifer Tang, Todd Sulchek
Keywords(s): AAXXXX, ABXXXX, Asymmetrical, AXXXXX, Bi-Functionalized, CAXXXX, CBXXXX, CCXXXX, CDC Docket Import, CDC Docket Import NP, CXXXXX, DAXXXX, DBXXXX, DDXXXX, DEXXXX, DXXXXX, IAXXXX, IBXXXX, ICXXXX, IXXXXX, Microparticles, PXXXXX, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XDXXXX, XFXXXX, XHXXXX, YBXXXX
Category(s): Collaboration Sought > Licensing, Application > Consumer Products, TherapeuticArea > Cardiology, Application > Non-Medical Devices, TherapeuticArea > Neurology, TherapeuticArea > Oncology, TherapeuticArea > Dental, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Vaccines, TherapeuticArea > Immunology, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, Application > Software / Apps, TherapeuticArea > Geriatrics, Application > Medical Devices, ResearchProducts > Research Equipment, Application > Diagnostics, ResearchProducts > Antibodies, Application > Research Materials
Signatures of Genetic Control in Digestive and Liver Disorders
Our technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of- care...
Published: 10/28/2024   |   Inventor(s): Ralph Peace, Nicolaas Fourie, Sarah Abey, Wendy Henderson
Keywords(s): Acid, Altered, CAXXXX, CXXXXX, Digestive, DISORDERS, Expressions, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Identification, IXXXXX, Listed LPM Vepa as of 4/15/2015, liver, MESSENGER, MICRO, miRNA, PHENOTYPE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Ribonucleic, RNA, Species, THERAPY
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology
Generation of Artificial Mutation Controls for Diagnostic Testing
This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls...
Published: 10/28/2024   |   Inventor(s): Laurina Williams
Keywords(s): AA1XXX, AA5XXX, AA6XXX, AAXXXX, ARTIFICIAL, AXXXXX, CA1AXX, CA1CXX, CA1XXX, CAXXXX, controls, CXXXXX, diagnostic, GAXXXX, GCXXXX, GXXXXX, IA1BXX, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IXXXXX, MUTATION, NA2XXX, OA2XXX, TESTING, VPXXXX, WBXXXX, WHXXXX, WIXXXX, WMXXXX, XBXXXX, XCXXXX, XEXXXX, YAXXXX, YBXXXX
Category(s): Collaboration Sought > Licensing, Application > Software / Apps, Application > Diagnostics, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Pulmonology, Application > Research Materials, TherapeuticArea > Ophthalmology, TherapeuticArea > Dental, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Consumer Products, TherapeuticArea > Oncology, TherapeuticArea > Neurology, ResearchProducts > Computational models/software, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024   |   Inventor(s): Christopher Bachran, Stephen Leppla
Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics
Engineered Anthrax Toxin Variants that Target Cancer
This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...
Published: 10/28/2024   |   Inventor(s): Stephen Leppla, Damilola Phillips, Clinton Leysath
Keywords(s): Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology
Pyruvate Kinase M2 Activators for the Treatment of Cancer
This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...
Published: 11/5/2024   |   Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas
Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024   |   Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath
Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases
Highly Potent and Selective Deubiquitinating Enzyme Inhibitor
Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...
Published: 10/28/2024   |   Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney
Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis
The integrity of the epidermis and mucosal epithelia is highly dependent on self-renewing stem cells and, therefore, is vulnerable to physical and chemical damage from common cancer treatments, such as radiation or chemotherapy. Consequently, many cancer patients undergoing these treatments develop mucositis, a debilitating condition involving painful...
Published: 10/28/2024   |   Inventor(s): Ramiro Iglesias-Bartolome, Vyomesh Patel, Ana Cotrim, Alfredo Molinolo, James Mitchell, J Silvio Gutkind
Keywords(s): CBXXXX, Cell, CXXXXX, Epithelial, inhibition, mTOR, Mucositis, PREVENTS, PROTECTS, Radiation-induced, Senescence, Stem
Category(s): Application > Therapeutics, TherapeuticArea > Oncology
1 2 3 4 5 6 7 8 9